SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is surging following record quarterly revenue and the milestone achievement of positive operating cash flow, signaling a significant transition toward profitability. Investors are actively discussing the company's shift from a pure medical device firm to a semiconductor-based AI imaging platform, with many weighing the impact of its strategic partnership with Midjourney against historical skepticism regarding share offerings and long-term cash burn.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors respond to a series of positive clinical trial results for its next-generation obesity treatment, retatrutide, alongside news of expanded insurance coverage for its core GLP-1 portfolio. The community is actively debating the company's long-term pipeline dominance and its strategic shift into broader therapeutic areas, including infectious disease and oncology, while tracking its momentum toward new record highs.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is capturing significant investor attention as its oral Wegovy tablet continues to exhibit rapid adoption, with new weekly prescriptions outpacing competitor GLP-1 pills. The community remains focused on whether this oral growth can offset competitive pressure from Eli Lilly and broader sector volatility, while analysts continue to adjust valuation models amid strong demand for metabolic treatments.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the announcement of a joint research agreement with Honda to develop solid-state battery technology and manufacturing processes, fueling investor optimism regarding long-term scaling potential. The community is actively debating the significance of this OEM validation versus the need for more concrete commercialization timelines, while keeping a close eye on upcoming earnings and potential future partner announcements.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense bearish sentiment and significant volatility as community members aggressively debate the sustainability of its debt-driven Bitcoin acquisition strategy and recent stock dilution. Investors remain deeply divided, with some highlighting the company's leverage as a potential systemic risk, while others view the current price compression as a long-term accumulation opportunity despite the ongoing downward pressure.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics (OPTX) is attracting heavy investor attention as the market positions it as a critical domestic supplier for the defense, space, and AI infrastructure sectors. Community discussion is currently focused on the company's ultra-precision manufacturing capabilities, its strategic positioning within U.S.-based supply chains, and the high potential for growth linked to LEO satellite and data center optics demand.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems is surging following an earnings report that highlighted a major acceleration in AI infrastructure orders, leading the company to raise its guidance and announce a strategic pivot toward high-growth networking segments. The community is actively debating whether this movement represents a legitimate structural re-rating of the stock into a key AI player or a speculative bubble reminiscent of the dot-com era.

TOSHI

TOSHI is trending as the community anticipates potential AI-driven utility announcements and product integrations within the Base ecosystem. Investors are actively discussing the token's role as a prominent cat-themed asset while sharing bullish sentiment regarding recent consolidation patterns and the possibility of a significant breakout.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors debate its role as a defensive safe haven amid broader market volatility and a rotation away from high-valuation tech stocks. The community is actively discussing the stock's potential for a rebound toward previous highs, fueled by expectations surrounding the upcoming shareholder meeting and continued strength in e-commerce and delivery operations despite ongoing economic pressures.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing community attention as investors debate its potential for a major price breakout, fueled by anticipation of upcoming network upgrades and persistent comparisons to Bitcoin's scalability. While some traders are expressing frustration over stagnant performance and questioning the network's long-term utility, bullish sentiment remains centered on the expectation of a 'flippening' or a significant rally toward higher resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?

Equity

Zevra Therapeutics shares saw a series of positive brokerage actions after the company asked the U.S. Food and Drug Administration to add a new patent for its Miplyffa drug to the Orange Book.

ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug

Zevra said in a statement that it has asked the U.S. Food and Drug Administration to add its new patent for its drug MIPLYFFA to its official list.


Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +184.36% and +15.51%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -29.46% and -15.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on Wednesday

Zevra Therapeutics (NASDAQ:ZVRA) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and seven have issued a buy...

Zevra Therapeutics (NASDAQ:ZVRA) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Zevra Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday...

Stratos Wealth Partners LTD. Boosts Stake in Zevra Therapeutics, Inc. $ZVRA

Stratos Wealth Partners LTD. increased its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 78.6% in the 4th quarter, according to its most recent filing with the SEC. The fund...

JPMorgan Chase & Co. Has $4.18 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRA

JPMorgan Chase & Co. lifted its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 1,458.8% in the third quarter, according to its most recent filing with the SEC. The firm...

Hennion & Walsh Asset Management Inc. Invests $1.25 Million in Zevra Therapeutics, Inc. $ZVRA

Hennion & Walsh Asset Management Inc. acquired a new stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 139,591 shares of the company's sto...

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.11	--	--	N/A
Q1 '26	$0.08	$0.60	639.73%	BEAT
Q4 '25	$0.05	$0.19	276.98%	BEAT
Q3 '25	-$0.03	-$0.01	70.37%	BEAT
Q2 '25	$2.26	$1.21	-46.55%	MISSED

ZVRAZevra Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest ZVRA News